PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Meeting Abstract
| Authors: | Choueiri, T. K.; Flaifel, A.; Xie, W.; Braun, D.; Ficial, M.; Jennings, R.; Nassar, A.; Escudier, B.; George, D. J.; Motzer, R. J.; Morris, M. J.; Powles, T.; Wang, E.; Huang, Y.; Freeman, G.; Signoretti, S. |
| Abstract Title: | PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | viii726 |
| Language: | English |
| ACCESSION: | WOS:000459277304393 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy424.040 |
| Notes: | Meeting Abstract: LBA34 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work